SELLAS wants to sell us an Immunotherapy for Mesothelioma

Screen Shot 2016 09 22 at 18.18.08

After Cyprus, we mosey back to the mainland to visit the country gave the world the cuckoo clock. That’s right, we’re Schweiz-bound. In Switzerland, we’ll meet an immuno-oncology biotech, SELLAS Life Sciences.


City: Zug (Zurich-area), Switzerland

Founded: 2012

Employees: 11 – 50

Financial Data: None available…what a secretive cohort.

Angelos M. Stergiou, CEO

Mission: SELLAS Life Sciences is a development-stage biopharmaceutical company focused on immunotherapies to treat multiple myeloma and ovarian cancer. It has branched out to mesothelioma, a cancer with a poor prognosis linked to the inhalation of asbestos.

Comment: The company just received Fast Track Designation for its lead candidate, Galinpepimut-S, which it licensed from Memorial Sloan Kettering Cancer Center. The treatment is currently performing admirably in Phase II clinical trials for Malignant Pleural Mesothelioma, inducing CD8 and CD4+ T cells with a favorable tolerability and safety profile.


Feature Image Credit: Labiotech Map

Explore other topics: CancerImmunotherapySwitzerland

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More